Baxter announced R&D collaboration with Dorizoe Lifesciences

| By | Baxter, Drug Development, Generics
0
2077

Baxter International Inc., a global medical products company, yesterday announced an agreement with Dorizoe Lifesciences Limited, a full-service global contract research and development (R&D) organization, that will facilitate accelerated development of more than 20 generic injectable products—including anti-infectives, oncolytics and cardiovascular medicines. Dorizoe will work with Baxter to perform certain product development activities, and Baxter will hold worldwide manufacturing and commercialization rights. Financial terms of the agreement were not disclosed.

“This partnership extends Baxter’s growing pipeline of generic injectables, further strengthening our portfolio with a broad range of high-quality essential medicines,” said Robert Felicelli, president, Pharmaceuticals, Baxter. “We look forward to working with Dorizoe to bring their highly skilled technical expertise together with Baxter’s manufacturing leadership and hospital channel strength to better serve the needs of patients around the world.”

Baxter estimates that the global sterile generic injectables segment is more than $40 billion, with a compound annual growth rate of approximately 10 percent (2010 – 2015). Baxter currently participates in a niche portion of the segment, producing difficult-to-manufacture oncology drugs and standard-dose, ready-to-use premixed injectable products.

Baxter recently announced plans to expand its presence in the space with the pending acquisition of Claris Injectables Limited (Claris). The acquisition of Claris, which is expected to close in the second half of 2017, will provide Baxter with a currently marketed portfolio of molecules in anesthesia and analgesics, renal, anti-infectives and critical care in a variety of presentations including bags, vials and ampoules along with a robust pipeline and high-quality manufacturing capabilities. Baxter also recently announced a strategic partnership with ScinoPharm—one of the world’s leading active pharmaceutical ingredient (API) manufacturers—to develop, manufacture and commercialize five generic injectables used in cancer treatment, with an option to add up to 15 additional injectable molecules.

Dorizoe provides services for pharmaceutical companies including formulation development, analytical development, tech transfer and regulatory filing support. This agreement will build upon Dorizoe’s R&D expertise and Baxter’s differentiated technologies, advanced manufacturing capabilities and global marketing and hospital channel presence to help accelerate the introduction of Baxter’s generic molecules into the market.

SOURCE: baxter
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.